When was Chembio founded?

Chembio was founded in 1986 and raised its 1st funding round 21 years after it was founded.

Where is Chembio located?

Chembio is headquartered in Medford, United States. It is registered at Medford, New York.

How many employees does Chembio have?

As of Sep 30, 2026, the latest employee count at Chembio is 112.

Is Chembio a funded company?

Chembio is a funded company, having raised an undisclosed amount across 8 funding rounds to date. The company's 1st funding round was a $***** Grant (prize money) round, raised on Jun 01, 2007.

How much is Chembio worth?

The last known valuation of Chembio was $***** as of Jan 31, 2023.

When was the latest funding round of Chembio?

Chembio's latest funding was a $***** Grant (prize money) round on Feb 06, 2026, with participation from 1 investor.

What is the annual revenue of Chembio?

Annual revenue of Chembio is between $10M and $50M as on Dec 31, 2022

Where does Chembio rank among its competitors?

Chembio ranks 1st amongst 23 active competitors, of which 3 are funded. It stands 6th in terms of total funding among its competitors. The most recent competitor to raise funding was Chembio, which secured $1.8M in Feb, 2026.

Who are the top competitors of Chembio?

Chembio's top competitors include BIOGENES TECHNOLOGIES, Chipcare and Sedia Biosciences. Among them, Chembio secured the most recent funding round in February, 2026.

Chembio - 2026 Company Profile, Funding & Competitors

Q: Is Chembio an acquired company?

Chembio got acquired by Biosynex on Jan 31, 2023.

Chembio is an acquired company based in Medford (United States), founded in 1986. It operates as a POC Diagnostics for Infectious Diseases using a proprietary immunoassay platform. Chembio has raised an undisclosed amount in funding, with last known valuation of $*****. The company has 23 active competitors, including 3 funded and 5 that have exited. Its top competitors include companies like BIOGENES TECHNOLOGIES, Chipcare and Sedia Biosciences.

Company Details

Chembio Diagnostics, Inc. specializes in proprietary rapid diagnostic tests. Chembio's two FDA PMA-approved, CLIA-waived, rapid HIV tests are marketed in the U.S. by Alere, Inc. Chembio markets its HIV STAT-PAK® line of rapid HIV tests internationally to government and donor-funded programs directly and through distributors. Chembio has developed a patented point-of-care test platform technology, the Dual Path Platform (DPP®) - a chromatographic immunoassay technology, which the company claims offers offers significant advantages over Lateral Flow (LF) technology.

Website: chembio.com
Social
Registered Address: Medford, New York

Key Metrics

Founded Year

1986

Location

Medford, United States

Stage

Acquired

Latest Funding Round

Grant (prize money), Feb 06, 2026, $*****

Last Known Valuation

$***** as on Jan 31, 2023

Investors

Perceptive Advisors & 2 more

Ranked

1^st among 23 active competitors

Annual Revenue

$10M - $50M as on Dec 31, 2022

Employee Count

112 as on Sep 30, 2026

Investment & Acquisitions

Orangelife Comercio E Industria

Similar Companies

BIOGENES TECHNOLOGIES & 29 more

Exit Details

Acquired by Biosynex (Jan 31, 2023)

View Chembio's full profile

Chembio is associated with 5 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
Chembio Diagnostics, Inc. CIN: 1092662 , United States, Active		$10M - $50M (As on Dec 31, 2022)	-	-
CHEMBIO DIAGNOSTICS, INC. CIN: 5006153 , United States, Active	Sep 09, 2016	-	-	-
CHEMBIO DIAGNOSTIC SYSTEMS INC. CIN: 1691110 , United States, Active	Jan 04, 1993	-	-	-
CHEMBIO DIAGNOSTICS, INC. CIN: 88-0425691 , United States, Active	Dec 31, 1985	-	-	-
CHEMBIO DIAGNOSTIC SYSTEMS, INC. CIN: 112813910 , United States, Active	Dec 26, 999	-	151 (As on Dec 31, 2024)	-

Chembio got acquired by Biosynex on Jan 31, 2023 at an acquisition amount of $*****.

Click here to take a look at Chembio's acquisition in detail

Chembio has raised funding over 8 rounds. Its first funding round was on Jun 01, 2007. Its latest funding round was a Grant (prize money) round on Feb 06, 2026 for $*****. 1 investor participated in its latest round. Chembio has 3 institutional investors.

Here is the list of recent funding rounds of Chembio:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Feb 06, 2026	4358005	Grant (prize money)	5646829	5445498	5690862	8426646
Sep 04, 2019	5329211	Conventional Debt	6043667	1641373	9423156	Perceptive Advisors
Feb 23, 2011	2702332	Grant (prize money)	7441616	7462223	3574062	HHS

Access funding benchmarks and valuations. Sign up today!

View details of Chembio's funding rounds and investors

Chembio's employee count trend

Chembio has 112 employees as of Sep 26. Here is Chembio's employee count trend over the years:

Uncover Chembio's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Chembio include BIOGENES TECHNOLOGIES, Chipcare and Sedia Biosciences. Here is the list of Top 10 competitors of Chembio, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Chembio 1986, Medford (United States), Acquired	POC Diagnostics for Infectious Diseases using a proprietary immunoassay platform	-	Perceptive Advisors, CARB-X & 1 others	54/100
2nd	BIOGENES TECHNOLOGIES 2015, Kajang (Malaysia), Series A	Developing technology in molecular diagnostics and genomics	$5.7M	Antler, MOSTI & 5 others	38/100
3rd	Chipcare 2009, Toronto (Canada), Deadpooled	Develops a hand-held blood test from a single drop of blood	$11.1M	Maple Leaf Angels, Canadian Space Agency & 5 others	33/100
4th	Sedia Biosciences 2009, Portland (United States), Seed	Advancing global healthcare access through innovative diagnostics and monitoring tools	$285K	NIAID, NIH SBIR/STTR & 2 others	31/100
5th	LabNow 2005, Austin (United States), Deadpooled	Domain registration verification service ensuring domain name resolution and preventing deletion	$21.6M	Austin Technology Incubator, Powershift Group ... & 1 others	31/100
6th	Premier Medical Corporation 1997, Valsad (India), Unfunded	Manufacturer of point-of-care rapid diagnostic tests for infectious diseases.	-	-	30/100
7th	RapiDx 2008, Tel Aviv (Israel), Seed	POC self testing test for detection of health conditions	$1M	TechnoPlus Ventures, Medvest	30/100
8th	UrSure 2015, Boston (United States), Acquired	Developer of a non-invasive mass spectrometry-based urine test to monitor adherence to the HIV preventive drug	-	MassChallenge, FHI Ventures	29/100
9th	Aldatu Biosciences 2014, Boston (United States), Funding Raised	Innovative PCR diagnostics for infectious diseases, advancing global health emergency response	-	Gaingels, MassChallenge & 3 others	28/100
10th	AccelevirDx 2015, Baltimore (United States), Funding Raised	Developer of diagnostic assays for HIV	-	HHS	28/100